Proton therapy in the management of non-Hodgkin lymphoma
نویسندگان
چکیده
Proton therapy (PT) is a highly conformal type of radiation therapy that can target the tumor while sparing dose to surrounding normal tissues. This study reviews a single institution's experience managing patients with non-Hodgkin lymphoma (NHL) treated with PT. Eleven patients with NHL were treated with PT from January 2008 to January 2014 on an institutional review board-approved outcomes tracking protocol, and included patients with indolent orbital lymphoma (n = 4), primary mediastinal B-cell lymphoma (n = 3), plasmablastic lymphoma (n = 2) and natural killer (NK) T-cell lymphoma (n = 2). The median follow-up was 38 months. The 2-year rate of local control was 91%, with one patient with NK T-cell lymphoma having recurrence in-field. Toxicities were limited to grade 2 at highest, during follow-up. PT is a feasible and effective treatment for NHL. Early outcomes are favorable. Longer follow-up and more patients are needed to confirm our findings.
منابع مشابه
Primary Cervical Non-Hodgkin Lymphoma; A Narrative Review
Gynecological lymphoma is one of the rarest tumors of the female organs that need to be kept in mind in a suspected patient due to its different management protocol. Even though the reported cases of ovarian lymphoma are not limited; our knowledge about diagnosis and treatment of primary cervical lymphoma is restricted. There is a rising number of suggested imaging and pathological criteria tha...
متن کاملConstruction and cloning of a recombinant expression vector containing human Cd20 Gene for antibody therapy in Non-Hodgkin Lymphoma
ABSTRACT Introduction: Non-Hodgkin lymphoma (NHL) is a cancer that starts in lymphocytes. The main treatment for NHL is chemotherapy and radiation. Today immunotherapy is a promising therapeutic approach in the treatment of a variety cancers which is high specific unlike previous methods. Antibodies do not penetrate effectively into tumore tissues because of their large size. Whe...
متن کاملCentral Mucoepidermoid Carcinoma with Non-Hodgkin Lymphoma: A Case Report
Introduction: Central mucoepidermoid carcinoma (CMEC) is a rare primary intraosseous bony lesion. The mandible is more commonly affected than the maxilla. CMEC is frequently misdiagnosed radiographically and clinically as a benign odontogenic tumor or cyst. Case Presentation: We present a rare case with a secondary malignant neoplasm. A male patient was initially diagnosed with B-cell non-Hodg...
متن کاملHead and Neck Lymphoma in an Iranian Population
Introduction: This study is aimed to assess the prevalence and characteristics of head and neck lymphoma in a defined group of an Iranian population. Materials and Methods: In this retrospective study, 126,450 biopsy reports from two referral Pathology Departments, (Tehran, the capital of Iran) were evaluated. In cases with head and neck lymphoma, other variables such as age, sex, specific lo...
متن کاملUnusual Presentation of T-cell non-Hodgkin Lymphoma with Multiple Skin Nodules
Non-Hodgkin lymphoma is very uncommon in infancy and skin as the primary site of involvement in Non-Hodgkin lymphoma is rarely encountered. We describe a 10-month-old infant with T-cell Non-Hodgkin lymphoma who presented with multiple skin nodules as the predominant feature of her disease. The clinical manifestations, treatment strategy and disease outcome are reviewed. Key words: Non-Hodgk...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کامل